The Elijah E. Cummings Lower Drug Costs Now Act: How It Would Work, How It Would Affect Prices, and What the Challenges Are April 9, 2020 | Issue Briefs Featured Will Medicare Prescription Drug Reform Legislation Make Insulin More Affordable?April 2, 2020 | Journal Article Pharmacy Benefit Managers: Practices, Controversies, and What Lies AheadMarch 26, 2019 | Issue Briefs Perverse Incentives: Why Brand-Name Drugs Can Cost Less Than Generics for Medicare BeneficiariesJuly 1, 2019 | Journal Article Reducing Wasteful Spending in Employers’ Pharmacy Benefit PlansAugust 30, 2019 | Issue Briefs Prescription drugs accounted for 17 percent of total U.S. health care spending — or about $457 billion — in 2015. And that share is expected to rise over the next decade as drug costs outpace those of all other health care services. Policymakers need unbiased information and insight into what drives pharmaceutical prices and spending so they can develop feasible, effective policy solutions. Leave this field blank Our Experts Lovisa GustafssonVice President, Controlling Health Care Costs Media Mention read on: CNBCJanuary 14, 2019 Here's why many prescription drugs in the US cost so much—and it's not innovation or improvement FDA Actions on Drug Pricing A Timeline Explore Timeline The Latest in Prescription Drugs Narrow by: Author Anderson, ChloeAnderson, GerardAnderson, Kelly E.Baumgartner, Jesse C.Beutel, SophieBishop, ShawnBlumenthal, DavidBrooks-LaSure, ChiquitaCall, AdrienneColeman, AkeiisaCollins, Sara R.Conti, RenaCorr, BillDavis, KarenDoty, Michelle M.Duong, SophiaDusetzina, Stacie B.Ex, PatriciaFowler, ElizabethFrank, Richard G.Fry, CarrieGabel, Jon R.Ginsburg, Paul B.Glied, Sherry A.Green, Matthew Gunja, Munira Z.Gustafsson, LovisaGuyer, JocelynHorvath, JaneJha, AshishJost, Timothy S.Kang, So YeonKenyatta, KahaariKeohane, Laura M.Kesselheim, Aaron S.LaRosa, JoshLieberman, Steven M.Llamas, AlyssaMann, CindyMartin, KristiMcDonald, RuthMorgan, StevenMoulds, DonaldNuzum, RachelOran, RebeccaOsborn, RobinPanteli, DimitraPapanicolas, IreneParasrampuria, SonalPaxton, IsabelRamsay, ChristinaRiley, TrishRobinson, James C.Rodwin, Marc A.Rother, JohnSarnak, Dana O.Schneider, Eric C.Schoen, CathySeeley, ElizabethSeervai, ShanoorSen, Aditi P.Shah, ArnavSharp, JeremySquires, DavidStromberg, SamVela, LaurenWaxman, HenryWhitmore, HeidiWillink, AmberWoskie, Liana R.Wynne, BillyZhu, Benjamin Date Last 7 daysLast 30 daysLast 6 monthsPast yearOver a year agoOver 2 years agoOver 3 years agoOver 4 years agoOver 5 years ago Type Fund ReportsTo The PointIssue BriefsExplainerInfographicJournal ArticlePodcast View By: Card View Card View List View Apply Leave this field blank To the Point It’s the Monopolies, Stupid! May 24, 2018 By David Blumenthal To the Point Trump Administration’s Prescription Drug “Blueprint” to Tackle High U.S. Prices Will Need More Action Steps May 17, 2018 By Shawn Bishop, Christina Ramsay, Lovisa Gustafsson Publication What Commissioner Gottlieb’s FDA Is Doing to Lower Prescription Drug Prices and Steps Congress Can Take to Help April 26, 2018 By Henry Waxman, Bill Corr, Kristi Martin, Sophia Duong To the Point Policy Prescriptions for High Drug Costs: Experts Weigh In April 3, 2018 By Shawn Bishop To the Point The U.S. Has Two Opioid Epidemics: The Federal Response Should Consider Both March 22, 2018 By Shanoor Seervai, Arnav Shah, Eric C. Schneider To the Point 340B Drug Discount Program: Why More Transparency Will Help Low-Income Communities March 15, 2018 By Rena Conti Publication Health Care Spending in the United States and Other High-Income Countries March 13, 2018 By Irene Papanicolas, Liana R. Woskie, Ashish Jha To the Point Bipartisan Deal Includes Important Step to Control Medicaid Drug Prices, But More Efforts Are Needed February 26, 2018 By Henry Waxman, Bill Corr, Kristi Martin To the Point Lower Drug Costs: The Next Frontier for State Flexibility February 20, 2018 By Trish Riley To the Point Trump Budget’s Prescription Drug Proposals Would Lower Patients’ Costs and Federal Spending; Some Could Lower Drug Prices February 13, 2018 By Henry Waxman, Bill Corr, Kristi Martin To the Point Three Key Health Issues Congress Could Consider in 2018 Budget Deal February 2, 2018 By David Blumenthal, Shanoor Seervai To the Point Bipartisan Bill Would Increase Competition Among Drug Manufacturers and Lower Drug Prices January 29, 2018 By Henry Waxman, Bill Corr, Kristi Martin Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Next page Next › Last page Last »
